Popular Articles
Stretch Mark Cream

AXURA(R)/AKATINOL(R) Enhances Communication Abilities In Patients With Alzheimer÷´s Disease - for A Longer Integration In Social And Family Life
Memantine improves functional communication skills in patients with moderate to severe Alzheimer"s disease (AD), noticeable by caregivers. These are the study results discussed at the International Conference on Alzheimer"s Disease (ICAD). The data of two recent clinical trials support that AXURA®/AKATINOL® - an uncompetitive NMDA receptor antagonist - effects language skills in AD patients and improves cognitive abilities and functional communication. Leading neurologists emphasize that improvement of communication skills is a meaningful treatment target. Communication breakdown can trigger feelings of frustration in Alzheimer"s patients and these feelings may manifest as behavioral instability. This in turn is known to be a major of caregiver"s burden and distress.
generic viagra online
CytRx's Tamibarotene Receives Positive Opinion From The Committee For Orphan Medicinal Products In The European Union For Treatment Of APL
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, announced that its lead drug candidate tamibarotene has received official notification from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) that a positive opinion was made regarding the application for orphan medicinal product for the treatment of acute promyelocytic leukemia (APL). The positive opinion of the COMP has now been forwarded to the EU commission for final approval and publication in the community register. This favorable opinion for tamibarotene in the European Union (EU) is in addition to the Orphan Drug Designation for APL and Fast Track Designation for the treatment of adult patients with relapsed or refractory APL following treatment with all-trans retinoic acid (ATRA) and arsenic trioxide granted by the U.S. Food and Drug Administration (FDA) in October 2007. Purchase zoloft to treat depression.
News of the day
Seattle Genetics To Present SGN-35 And Lintuzumab Clinical Data At The European Hematology Association Congress
Seattle Genetics, Inc. (Nasdaq:SGEN) announced that data from a phase I clinical trial evaluating every three week dosing of SGN-35 and a phase I clinical trial of lintuzumab (SGN-33) will be reported at the 14th Congress of the European Hematology Association (EHA) being held June 4-7, 2009 in Berlin, Germany. The abstracts are available from the EHA website at http://www.ehaweb.org.

What Is Edema? What Causes Edema?

Edema, is swelling caused by fluid retention - excess fluid is trapped in the body"s tissues. In the UK/Ireland/Australasia and some other countries the word is spelled oedema. Swelling caused by edema commonly occurs in the hands, arms, ankles, legs and feet. It is usually linked to the venous or lymphatic systems. Edema was formerly known as dropsy or hydropsy. Edema may be generalized or local. It can appear suddenly, but usually develops subtly - the patient may first gain weight, or wake up with puffy eyes. Many patients wait until symptoms are well advanced before seeking medical help.

Exploring The Complexity Of Symbiosis In DNA And Cell Biology.

The unique association between microorganisms and their hosts, whether insects, plants, or mammals, provides a fascinating view into how microbial symbionts adapt to changing biological environments. Insights into the diversity and complexity of symbiotic relationships are the focus of the current special issue of DNA and Cell Biology, a peer-reviewed journal published by Mary Ann Liebert, Inc. The issue is available free online at http://www.liebertpub.com/dna "Symbiosis is one of the most rapidly growing fields in biology.... After decades of focusing on bacteria in pure culture, it is evident that to manage them for our benefit, we need to understand bacteria in association with the complex biological environments with which they contend in the natural world," write Jo Handelsman, PhD, Editor-in-Chief of DNA and Cell Biology, Professor at the University of Wisconsin-Madison, and President of the Rosalind Franklin Society, and Guest Editor Margaret J. McFall-Ngai, Professor at the University of Wisconsin-Madison, in their Editorial.

Over 50 Pharmacists Trained Up For NPA's Seasonal Flu Vaccination Service.

Over 50 pharmacists have been trained to provide seasonal flu vaccinations under a private Patient Group Direction that the NPA is facilitating. Training days were conducted in London and Birmingham with further training days scheduled at the start of September 2009 in Newport, Durham, St Albans and Haydock. Raj Nutan, NPA Head of Business Development said: "Members were telling us that the burden of regulation was frustrating them if they wished to supply prescription medicines via private patient group directions. So we have embarked on developing a series of PGD opportunities that will provide them with a means of clearing the regulatory hurdle effortlessly. A bonus for NPA members is that they won"t need additional insurance - NPA Insurance already covers the pharmacist for providing this NPA service.

FDA Issues Final Regulation On Dental Amalgam.

The U.S. Food and Drug Administration issued a final regulation classifying dental amalgam and its component parts - elemental mercury and a powder alloy-used in dental fillings. While elemental mercury has been associated with adverse health effects at high exposures, the levels released by dental amalgam fillings are not high enough to cause harm in patients. The regulation classifies dental amalgam into Class II (moderate risk). By classifying a device into Class II, the FDA can impose special controls (in addition to general controls such as good manufacturing practices that apply to all medical devices regardless of risk) to provide reasonable assurance of the safety and effectiveness of the device.